- [Resource Hub](/) - [Publication](/?resource-type=publication#library) - A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer # A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer Blau CA, Ramirez AB, Blau S, Pritchard CC, Dorschner MO, Schmechel SC, et al. Journal of the National Comprehensive Cancer Network . 2016;14(1):8-17. DOI [10.6004/jnccn.2016.0003](https://doi.org/10.6004/jnccn.2016.0003). PMID 26733551. PMCID PMC4970582. How to cite ### AMA Blau CA, Ramirez AB, Blau S, Pritchard CC, Dorschner MO, Schmechel SC, et al. A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. J Natl Compr Canc Netw . 2016;14(1):8-17. doi:10.6004/jnccn.2016.0003 ### APA Blau, C. A., Ramirez, A. B., Blau, S., Pritchard, C. C., Dorschner, M. O., Schmechel, S. C., et al. (2016). A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network , 14(1), 8-17. https://doi.org/10.6004/jnccn.2016.0003 ### BibTeX @article{blau2016distributed, title = {A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer}, author = {Blau, C. A. and Ramirez, A. B. and Blau, S. and Pritchard, C. C. and Dorschner, M. O. and Schmechel, S. C. and others}, journal = {Journal of the National Comprehensive Cancer Network}, volume = {14}, number = {1}, pages = {8--17}, year = {2016}, doi = {10.6004/jnccn.2016.0003}, pmid = {26733551} } Judging whether a treatment is working in breast cancer that has spread to bone is hard. Standard imaging changes slowly, and a bone-marrow biopsy is a single snapshot of a moving target. In this ITOMIC-001 report, a distributed network of 32 researchers from 14 institutions followed one patient with metastatic triple-negative breast cancer, sampling her circulating tumor cells 48 times over 9 months alongside whole-exome and RNA sequencing and a differential drug screen. The CTC counts — total cells, fragments and clusters — tracked her response to cisplatin, crizotinib and eribulin more sensitively than conventional blood markers. A rise in CTC clusters preceded her death, and a drug screen run on her enriched CTCs pointed to vulnerabilities a single biopsy would have missed. [Read publication at Journal of the National Comprehensive Cancer Network](https://pmc.ncbi.nlm.nih.gov/articles/PMC4970582/) ## Key findings - Circulating tumor cells were monitored 48 times across 9 months in a single patient. A distributed network of 32 researchers from 14 institutions tracked total CTCs (about 1,500/mL at baseline), CD45−/EpCAM+/CK+ CTC fragments and CTC clusters as a longitudinal readout of response. - CTC dynamics tracked therapy response more sensitively than standard markers. Seven days after the first cisplatin dose, CTC fragments rose more than 100-fold; both CTCs and fragments then fell more than 650-fold and 3,500-fold respectively, ahead of changes in the CA15-3 blood marker. - A differential drug screen on enriched CTCs flagged BH3-mimetic sensitivity. Of 160 drugs tested on about 70 million CTCs enriched to roughly 12% purity, only the BCL-2 inhibitors ABT-263 and ABT-737 showed preferential activity, a signal reproduced across 20 triple-negative breast cancer cell lines (r=0.89). ## RareCyte in the methods “Assessments of circulating tumor cells (CTCs) were performed as described.” — Blau et al., Journal of the National Comprehensive Cancer Network (2016), Methods, “Circulating Tumor Cell Assays” Disclosure: RareCyte is listed as an author affiliation on the publication cited above. ## Why it matters for RareCyte users If you follow patients with rare circulating tumor cells, read this for what a repeated CTC measurement can carry. Here it caught response, resistance and relapse across 48 timepoints, when the standard blood marker lagged behind. One thing to be clear about as you weigh it. This paper does not name a CTC platform in its own methods; the assays were “performed as described,” pointing to an earlier protocol rather than to an instrument. What the record does add is that three of its authors work for RareCyte, noted in the disclosure below, and the method it cites is RareCyte’s own CTC-detection workflow. So take this as evidence for the kind of longitudinal rare-cell monitoring RareCyte is built around, not as a named-instrument benchmark. If that cadence fits your study — many timepoints from a single blood draw each — the value here is the time course, not any one count. [Back to all resources](/#library) ## Related resources [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026 ### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes. [View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026 ### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research [Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026 ### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026 ### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma [View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026 ### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025 ### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis [View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025 ### A novel device for buffy coat collection [View Publication](https://doi.org/10.1080/07366205.2025.2534299) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025 ### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025 ### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) CyteFinder Cellular and Molecular Life Sciences 2025 ### Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) CyteFinder Nature Medicine 2025 ### Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf) CyteFinder Orion 2024 ### Next Gen Liquid Biopsy: Comprehensive Analysis from a Single Tube of Blood [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf)